Overview

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

Status:
Completed
Trial end date:
2024-05-06
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the current process (CMC2).
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie